PHASE II STUDY OF 1592U89 &INDINAVIR IN HIV (ACTG368)

$73,467M01FY2002RRNIH

University Of Kentucky, Lexington KY

Investigators

Linked publications & trials

Paper 37694581 Paper 37485628 Paper 37485600 Paper 36172803 Paper 35151024 Paper 35108352 Paper 34918583 Paper 33248391 Paper 33152673 Paper 33152672 Paper 33091844 Paper 33091843 Paper 33091842 Paper 33086156 Paper 33075691 Paper 33070058 Paper 33059200 Paper 30855313 Paper 29334345 Paper 27720816 Paper 27411977 Paper 27401014 Paper 26914834 Paper 26855961 Paper 26407063 Paper 26347856 Paper 25556571 Paper 25420182 Paper 24879575 Paper 24651682 Paper 24636665 Paper 24525639 Paper 24522445 Paper 24510678 Paper 24467369 Paper 24408885 Paper 24354534 Paper 24163495 Paper 24062026 Paper 23663814 Paper 23627408 Paper 23523462 Paper 23372023 Paper 23306168 Paper 23283567 Paper 23245937 Paper 23076798 Paper 23021916 Paper 22769406 Paper 22746258 Paper 22708535 Paper 22366586 Paper 22289394 Paper 22209386 Paper 22126530 Paper 22119370 Paper 22062498 Paper 22054720 Paper 22049233 Paper 21872146 Paper 21610203 Paper 21480939 Paper 21453974 Paper 21453972 Paper 21440871 Paper 21437349 Paper 21324406 Paper 21271789 Paper 21071279 Paper 20919999 Paper 20880053 Paper 20720096 Paper 20635288 Paper 20610233 Paper 20587469 Paper 20561853 Paper 20539161 Paper 20229694 Paper 20142026 Paper 20109483 Paper 20038509 Paper 19949319 Paper 19880958 Paper 19820013 Paper 19694196 Paper 19618788 Paper 19563294 Paper 19556448 Paper 19556409 Paper 19527448 Paper 19387276 Paper 19323617 Paper 19318928 Paper 19195786 Paper 19185635 Paper 19115099 Paper 19092554 Paper 19070276 Paper 19018520 Paper 18926645

Abstract

This study is a phase II, placebo-controlled trial of 1592U89 in combination with open-label Indinavir sulfate and DMP-266 in HIV-infected subjects with nucleoside analog experience. This is a roll-over study of ACTG320.

View original record on NIH RePORTER →